Literature DB >> 11349064

Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf(1)) attenuates the virulence of uropathogenic Escherichia coli.

K E Rippere-Lampe1, A D O'Brien, R Conran, H A Lockman.   

Abstract

Cytotoxic necrotizing factor type 1 (CNF1) is a 115-kDa toxin that activates Rho GTPases and is produced by uropathogenic Escherichia coli (UPEC). While both epidemiological studies that link CNF1 production by E. coli with urinary tract disease and the cytopathic effects of CNF1 on cultured urinary tract cells are suggestive of a role for the toxin as a UPEC virulence factor, few in vivo studies to test this possibility have been reported. Therefore, in this investigation, we evaluated the importance of CNF1 in a murine model of urinary tract infection (UTI) by comparing the degree of colonization and damage induced by three different CNF1-producing E. coli strains with isogenic CNF1-deficient derivatives. The data from single-strain challenge experiments with C3H/HeOuJ mice indicated a trend toward higher counts of the wild-type strains in the urine and bladders of these animals up to 3 days after challenge in two of three strain pairs. Furthermore, this difference was statistically significant at day 2 of infection with one strain pair, C189 and C189cnf(1). To control for the animal-to-animal variability inherent in this model, we infected C3H/HeOuJ mice with a mixture of CNF1-positive and -negative isogenic derivatives of CP9. The CNF1-positive strain was recovered in higher numbers than the CNF1-negative strain in the urine, bladders, and kidneys of the mice up to 9 days postinfection. These striking coinfection findings, taken with the trends observed in single-strain infections, led us to conclude that CNF1-negative strains were generally attenuated compared to the wild type in the C3H/HeOuJ mouse model of UTI. Furthermore, histopathological examination of bladder specimens from mice infected with CNF1-positive strains consistently showed deeper, more extensive inflammation than in those infected with the isogenic mutants. Lastly, we found that CNF1-positive strain CP9 was better able to resist killing by fresh human neutrophils than were CP9cnf(1) bacteria. From these data in aggregate, we propose that CNF1 production increases the capacity of UPEC strains to resist killing by neutrophils, which in turn permits these bacteria to gain access to deeper tissue and persist better in the lower urinary tract.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349064      PMCID: PMC98434          DOI: 10.1128/IAI.69.6.3954-3964.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Identification of the region of rho involved in substrate recognition by Escherichia coli cytotoxic necrotizing factor 1 (CNF1).

Authors:  M Lerm; G Schmidt; U M Goehring; J Schirmer; K Aktories
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

2.  Effect of cytotoxic necrotizing factor-1 on actin cytoskeleton in human monocytes: role in the regulation of integrin-dependent phagocytosis.

Authors:  C Capo; S Meconi; M V Sanguedolce; N Bardin; G Flatau; P Boquet; J L Mege
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

3.  Activation of Rho GTPases by Escherichia coli cytotoxic necrotizing factor 1 increases intestinal permeability in Caco-2 cells.

Authors:  R Gerhard; G Schmidt; F Hofmann; K Aktories
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

4.  Hinderance of apoptosis and phagocytic behaviour induced by Escherichia coli cytotoxic necrotizing factor 1: two related activities in epithelial cells.

Authors:  C Fiorentini; A Fabbri; P Matarrese; L Falzano; P Boquet; W Malorni
Journal:  Biochem Biophys Res Commun       Date:  1997-12-18       Impact factor: 3.575

5.  Escherichia coli cytotoxic necrotizing factor 1 effaces microvilli and decreases transmigration of polymorphonuclear leukocytes in intestinal T84 epithelial cell monolayers.

Authors:  P Hofman; G Flatau; E Selva; M Gauthier; G Le Negrate; C Fiorentini; B Rossi; P Boquet
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains.

Authors:  W J Hopkins; A Gendron-Fitzpatrick; E Balish; D T Uehling
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

7.  Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine.

Authors:  G Flatau; E Lemichez; M Gauthier; P Chardin; S Paris; C Fiorentini; P Boquet
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

8.  Characterization of the roles of hemolysin and other toxins in enteropathy caused by alpha-hemolytic Escherichia coli linked to human diarrhea.

Authors:  S J Elliott; S Srinivas; M J Albert; K Alam; R M Robins-Browne; S T Gunzburg; B J Mee; B J Chang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 9.  Diagnosis and treatment of uncomplicated urinary tract infection.

Authors:  T M Hooton; W E Stamm
Journal:  Infect Dis Clin North Am       Date:  1997-09       Impact factor: 5.982

10.  Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice.

Authors:  D E Johnson; C V Lockatell; R G Russell; J R Hebel; M D Island; A Stapleton; W E Stamm; J W Warren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more
  61 in total

1.  Cytotoxic necrotizing factor from Escherichia coli induces RhoA-dependent expression of the cyclooxygenase-2 Gene.

Authors:  W Thomas; Z K Ascott; D Harmey; L W Slice; E Rozengurt; A J Lax
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Loss of regulatory protein RfaH attenuates virulence of uropathogenic Escherichia coli.

Authors:  Gábor Nagy; Ulrich Dobrindt; György Schneider; A Salam Khan; Jörg Hacker; Levente Emödy
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

3.  High-frequency secondary mutations after suicide-driven allelic exchange mutagenesis in extraintestinal pathogenic Escherichia coli.

Authors:  James R Johnson; Hank A Lockman; Krista Owens; Srdjan Jelacic; Phillip I Tarr
Journal:  J Bacteriol       Date:  2003-09       Impact factor: 3.490

Review 4.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

Review 5.  Switching Rho GTPase activation into effective antibacterial defenses requires the caspase-1/IL-1beta signaling axis.

Authors:  Laurent Boyer; Emmanuel Lemichez
Journal:  Small GTPases       Date:  2015-10-22

6.  Cytotoxic necrotizing factor type 1 production by uropathogenic Escherichia coli modulates polymorphonuclear leukocyte function.

Authors:  Jon M Davis; Susan B Rasmussen; Alison D O'Brien
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 7.  Covert operations of uropathogenic Escherichia coli within the urinary tract.

Authors:  Jean M Bower; Danelle S Eto; Matthew A Mulvey
Journal:  Traffic       Date:  2005-01       Impact factor: 6.215

8.  Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.

Authors:  Jon M Davis; Humberto M Carvalho; Susan B Rasmussen; Alison D O'Brien
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

9.  Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder.

Authors:  Tamako A Garcia; Christy L Ventura; Mark A Smith; D Scott Merrell; Alison D O'Brien
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

10.  In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA.

Authors:  Brian J Haugen; Shahaireen Pellett; Peter Redford; Holly L Hamilton; Paula L Roesch; Rodney A Welch
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.